Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Tamoxifène oral vs TamGel vs témoin chez les femmes atteintes d'hyperplasie atypique ou de carcinome lobulaire in situ

31 août 2026 mis à jour par: Mayo Clinic

Un essai randomisé de phase IIB comparant le tamoxifène oral à un gel topique de 4-hydroxytamoxifène à un groupe témoin chez des femmes atteintes d'hyperplasie atypique ou de carcinome lobulaire in situ

The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).

Aperçu de l'étude

Description détaillée

Women with atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) are at increased risk of breast cancer (BC) (~1-2 % per year). Over two decades ago, placebo-controlled randomized trials established that oral tamoxifen (20 mg/day) reduces breast cancer risk by 50% in generally defined high risk women, with ~70% reduction in women at high risk specifically due to atypical hyperplasia.[1] Years later, the side effects and toxicity of oral tamoxifen at 20 mg/day remain a significant barrier to its uptake and longterm compliance.[2, 3] To address the issue of toxicity, two main strategies have been pursued: 1) using a lower dose of oral tamoxifen, and 2) using a topical formulation of tamoxifen to avoid systemic side effects. The investigators will perform a prospective study of women with AH or LCIS who will take a short course of prevention therapy; breast tissue samples will be evaluated pre- and post-therapy to identify and evaluate very early biomarkers of response. The overall goal of the study is to evaluate short-term changes in background breast tissue induced by either low-dose oral tamoxifen or topical 4-OHT gel in women with AH or LCIS.

Type d'étude

Interventionnel

Inscription (Réel)

65

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Illinois
      • Evanston, Illinois, États-Unis, 60208
        • Northwestern University
    • Minnesota
      • Rochester, Minnesota, États-Unis, 55905
        • Mayo Clinic
    • New Jersey
      • Camden, New Jersey, États-Unis, 08103
        • MD Anderson Cancer center at Cooper

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 80 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Femelle

La description

Inclusion Criteria:

  • Willing to return to enrolling institution for follow-up

  • Willing to complete required testing

  • Ability to complete questionnaire by themselves or with assistance

  • Female (sex that was assigned at birth)

  • Ipsilateral intact breast with histology confirmation of atypical ductal or lobular hyperplasia, or lobular carcinoma in situ (LCIS), within the last 12 months, whether surgically excised or not.; OR neither AH nor LCIS but increased breast cancer risk defined as either:

    • Gail model (Breast Cancer Risk Assessment Tool) 5 year breast cancer risk of >= 3%, or
    • International Breast Intervention Study model 10 year breast cancer risk of >= 5%.
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)

  • The effects of topical afimoxifene (4-OHT) gel on the developing human fetus at the recommended therapeutic dose are unknown. However, oral tamoxifen is Pregnancy Category D-positive evidence of human fetal risk. For this reason, and because triphenylethylene antiestrogens, including tamoxifen, are known to be teratogenic, women of childbearing potential and their male partners must agree to use at least one effective form of birth control (abstinence is not an allowed method) prior to study entry and for the duration of study participation, and for 2 months following the last dose of study medications (participant can resume oral birth control pills for effective birth control measures after post-treatment biopsy is done). Effective birth control methods during treatment are: copper and Mirena intrauterine device (IUD), diaphragm/cervical cap/shield, spermicide, contraceptive sponge, condoms. Tubal Ligation is an acceptable method of birth control. Women of childbearing potential must have a negative pregnancy test within five days before starting study medications. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.

  • Willingness to avoid exposing breast skin to natural or artificial sunlight (i.e. tanning beds) for the duration of the study.

  • Participants must have acceptable organ and marrow function as judged by treating physician's evaluation of baseline laboratory data.

  • Negative pregnancy (serum or urine) test if of childbearing potential and/or follicle stimulating hormone (FSH) to verify menopausal status.

Exclusion Criteria:

  • Clinically suspicious mass/lesions

  • Breast cancer in the past 5 years.

  • Patients with any history of venous thromboembolic disease, regardless of timeframe (history of varicose veins and superficial phlebitis is allowed).

  • Current pregnancy or lactation.

  • History of other prior breast cancer-specific therapy within the previous 2 years (chemotherapy, anti-HER2 agents, endocrine agents, everolimus, CDK4-6 inhibitors).

  • Cytotoxic chemotherapy for any indication in last 2 years.

  • Prior use of selective estrogen receptor modulator (SERMS) or AIs including tamoxifen, raloxifene, anastrozole, letrozole, or exemestane for prevention or therapy within the past 5 years unless:

    • Use was less than 6 months duration in the past 5 years and not used in the 1 year prior to enrollment, or
    • Use was no greater than 2 months duration in the past 1 year and not used in the 6 months prior to enrollment.
  • Exogenous sex steroid, including oral contraceptive pill use within 1 month prior to pretreatment breast biopsy. Use of vaginally administered estrogens and hormone coated IUD such as Mirena is permitted.

  • History of any prior ipsilateral breast radiotherapy. Previous unilateral radiation of the contralateral side is allowed.

  • Skin lesions on the breast that disrupt the stratum corneum (e.g., eczema, ulceration).

  • History of endometrial neoplasia

  • Current smoker. Cessation for at least 6 weeks

  • Current users of potent inhibitors of tamoxifen metabolism. The potent inhibitors of tamoxifen metabolism are: bupropion, cinacalcet, fluoxetine, paroxetine, quinidine.

  • Participants may not be receiving any other investigational agents within 90 days of enrollment or during this study.

  • History of allergic reactions to tamoxifen.

  • Uncontrolled intercurrent illness that in the judgement of the treating physician would make them unsuitable for study participation

  • Current use of anticoagulation medications.

  • Patients who are breastfeeding.

  • Hemoglobin < 10 g/dL (within 30 days of randomization).

  • Leukocytes < 3,000/microliter (within 30 days of randomization).

  • Platelets < 100,000/microliter (within 30 days of randomization).

  • Total bilirubin > 1.5 x institutional upper limit of normal (ULN) (within 30 days of randomization).

  • Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT) > 1.5 x ULN (within 30 days of randomization).

  • Alanine aminotransferase (ALT) serum glutamate pyruvate transaminase (SGPT) > 1.5 x ULN (within 30 days of randomization).

  • Alkaline phosphatase, S > 1.5 x ULN (within 30 days of randomization).

  • Albumin, S > 1.5 x ULN (within 30 days of randomization).

  • Protein, total, S > 1.5 x ULN (within 30 days of randomization).

  • Creatinine > 1.5 x ULN (within 30 days of randomization).

  • Antithrombin III <80% of normal.

  • Fibrinogen >1000 mg/dL.

  • Patients who are taking any medications, herbal products, or over the counter (OTC) products that are moderate or strong CYP2D6 inhibitors or CYP3A inducers. Patients should also refrain from starting any drug or product with these properties during the study. This is to avoid any potential interactions with tamoxifen or 4-OHT.

  • Clinically significant arrhythmia requiring ongoing medication for control / treatment, especially those with high risk of QT prolonging effects.

  • Identification of a clinically suspicious mass on examination.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Oral Tamoxifen 10 mg/day

Oral Tamoxifen 10 mg/day

Ancillary studies

Oral Tamoxifen 10 mg/day

Autres noms:
  • Tamoxifène oral
Expérimental: Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day

Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day

+oral placebo

Ancillary studies

Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day

Autres noms:
  • Gel topique
Expérimental: Control

Oral and gel placebo

Ancillary studies

placebo pill or placebo gel

Autres noms:
  • pilule placebo
  • gel placebo

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in Median Lobular Ki67 From Pre-Tamoxifen Breast Biopsy to On-Tamoxifen Biopsy With 4 Weeks of Intervention
Délai: Pre-biopsy to post-biopsy following 4 weeks of intervention

All patients received an oral pill and a topical gel. Prior to assessing non-inferiority of 4-OHT Gel compared to Oral Tamoxifen, treatment effect was assessed within each group by testing for a significant reduction in median lobular Ki67 between PreTam and OnTam biopsy. Median lobular Ki67 is assessed using the percentage of cells stained across all lobules separately at PreTam and OnTam timepoints, evaluated for a difference in median calculated change.

Pre-biopsy to post-biopsy following 4 weeks of intervention

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Amy Degnim, M.D., Mayo Clinic

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

26 juillet 2021

Achèvement primaire (Réel)

15 octobre 2024

Achèvement de l'étude (Réel)

15 octobre 2024

Dates d'inscription aux études

Première soumission

28 septembre 2020

Première soumission répondant aux critères de contrôle qualité

29 septembre 2020

Première publication (Réel)

30 septembre 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

24 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

31 août 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner